87 related articles for article (PubMed ID: 15292364)
1. Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density.
Jain A; Fedarko NS; Collins MT; Gelman R; Ankrom MA; Tayback M; Fisher LW
J Clin Endocrinol Metab; 2004 Aug; 89(8):4158-61. PubMed ID: 15292364
[TBL] [Abstract][Full Text] [Related]
2. Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets.
Bresler D; Bruder J; Mohnike K; Fraser WD; Rowe PS
J Endocrinol; 2004 Dec; 183(3):R1-9. PubMed ID: 15590969
[TBL] [Abstract][Full Text] [Related]
3. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia.
Rowe PS; de Zoysa PA; Dong R; Wang HR; White KE; Econs MJ; Oudet CL
Genomics; 2000 Jul; 67(1):54-68. PubMed ID: 10945470
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast Growth Factor-23 and Matrix Extracellular Phosphoglycoprotein Levels in Healthy Children and, Pregnant and Puerperal Women.
Ozsen A; Furman A; Guran T; Bereket A; Turan S
Horm Res Paediatr; 2019; 92(5):302-310. PubMed ID: 32187608
[TBL] [Abstract][Full Text] [Related]
5. Matrix extracellular phosphoglycoprotein (MEPE) correlates with serum phosphorus prior to and during octreotide treatment and following excisional surgery in hypophosphatemic linear sebaceous nevus syndrome.
Hoffman WH; Jain A; Chen H; Fedarko NS
Am J Med Genet A; 2008 Aug; 146A(16):2164-8. PubMed ID: 18627046
[No Abstract] [Full Text] [Related]
6. Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone.
Nampei A; Hashimoto J; Hayashida K; Tsuboi H; Shi K; Tsuji I; Miyashita H; Yamada T; Matsukawa N; Matsumoto M; Morimoto S; Ogihara T; Ochi T; Yoshikawa H
J Bone Miner Metab; 2004; 22(3):176-84. PubMed ID: 15108058
[TBL] [Abstract][Full Text] [Related]
7. Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone.
Argiro L; Desbarats M; Glorieux FH; Ecarot B
Genomics; 2001 Jun; 74(3):342-51. PubMed ID: 11414762
[TBL] [Abstract][Full Text] [Related]
8. MEPE has the properties of an osteoblastic phosphatonin and minhibin.
Rowe PS; Kumagai Y; Gutierrez G; Garrett IR; Blacher R; Rosen D; Cundy J; Navvab S; Chen D; Drezner MK; Quarles LD; Mundy GR
Bone; 2004 Feb; 34(2):303-19. PubMed ID: 14962809
[TBL] [Abstract][Full Text] [Related]
9. A synthetic peptide fragment of human MEPE stimulates new bone formation in vitro and in vivo.
Hayashibara T; Hiraga T; Yi B; Nomizu M; Kumagai Y; Nishimura R; Yoneda T
J Bone Miner Res; 2004 Mar; 19(3):455-62. PubMed ID: 15040834
[TBL] [Abstract][Full Text] [Related]
10. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.
Quarles LD
Am J Physiol Endocrinol Metab; 2003 Jul; 285(1):E1-9. PubMed ID: 12791601
[TBL] [Abstract][Full Text] [Related]
11. Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator.
David V; Martin A; Hedge AM; Rowe PS
Endocrinology; 2009 Sep; 150(9):4012-23. PubMed ID: 19520780
[TBL] [Abstract][Full Text] [Related]
12. Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia.
Liu S; Brown TA; Zhou J; Xiao ZS; Awad H; Guilak F; Quarles LD
J Am Soc Nephrol; 2005 Jun; 16(6):1645-53. PubMed ID: 15843468
[TBL] [Abstract][Full Text] [Related]
13. Matrix extracellular phosphoglycoprotein is expressed in causative tumors of oncogenic osteomalacia.
Imanishi Y; Hashimoto J; Ando W; Kobayashi K; Ueda T; Nagata Y; Miyauchi A; Koyano HM; Kaji H; Saito T; Oba K; Komatsu Y; Morioka T; Mori K; Miki T; Inaba M
J Bone Miner Metab; 2012 Jan; 30(1):93-9. PubMed ID: 21739089
[TBL] [Abstract][Full Text] [Related]
14. The effect of matrix extracellular phosphoglycoprotein and its downstream osteogenesis-related gene expression on the proliferation and differentiation of human dental pulp cells.
Wei X; Liu L; Zhou X; Zhang F; Ling J
J Endod; 2012 Mar; 38(3):330-8. PubMed ID: 22341070
[TBL] [Abstract][Full Text] [Related]
15. ASARM-truncated MEPE and AC-100 enhance osteogenesis by promoting osteoprogenitor adhesion.
Sprowson AP; McCaskie AW; Birch MA
J Orthop Res; 2008 Sep; 26(9):1256-62. PubMed ID: 18383145
[TBL] [Abstract][Full Text] [Related]
16. Evidence of downregulation of matrix extracellular phosphoglycoprotein during terminal differentiation in human osteoblasts.
Siggelkow H; Schmidt E; Hennies B; Hüfner M
Bone; 2004 Aug; 35(2):570-6. PubMed ID: 15268910
[TBL] [Abstract][Full Text] [Related]
17. Effect of serum fibroblast growth factor-23, matrix Gla protein and Fetuin-A in predicting osteoporosis in maintenance hemodialysis patients.
Wu Q; Xiao DM; Fan WF; Ye XW; Niu JY; Gu Y
Ther Apher Dial; 2014 Oct; 18(5):427-33. PubMed ID: 25196492
[TBL] [Abstract][Full Text] [Related]
18. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
19. Active sites of human MEPE-ASARM regulating bone matrix mineralization.
Minamizaki T; Sakurai K; Hayashi I; Toshishige M; Yoshioka H; Kozai K; Yoshiko Y
Mol Cell Endocrinol; 2020 Nov; 517():110931. PubMed ID: 32712387
[TBL] [Abstract][Full Text] [Related]
20. Age dependent regulation of bone-mass and renal function by the MEPE ASARM-motif.
Zelenchuk LV; Hedge AM; Rowe PS
Bone; 2015 Oct; 79():131-42. PubMed ID: 26051469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
